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Abstract
Background: Colistin-resistant/carbapenem-resistant Acinetobacter baumannii is a significant challenge for antibiotic
treatment and infection control policies. Since 2012, in Central Greece an increase of colistin/pan- resistant A. baumannii
has occurred, indicating the need for further analysis.
Methods: A total of 86 colistin-resistant/carbapenem-resistant out of 1228 A. baumannii clinical isolates, consecutively
collected between 2012 and 2014 in a tertiary Greek hospital of Central Greece, as well as one environmental isolate from
surveillance cultures were studied. Molecular typing and mechanisms of resistance to colistin and to carbapenems were
assessed, whereas, epidemiological and clinical data of the patients were reviewed.
Results: During the study period, the rate of colistin resistance gradually increased and reached 21.1 % in 2014.
All colistin-resistant/carbapenem-resistant A. baumannii belonged to 3LST ST101 clone that corresponds to the
international clonal lineage II. Carbapenem resistance was associated with the presence of blaoxa-23-like, while resistance
to colistin probably correlated with G54E and R109H amino acid substitutions in PmrA and PmrC, respectively.
Conclusions: Epidemiological data of the patients indicated that the first detection of colistin-resistant/
carbapenem-resistant ST101 clone in the University Hospital of Larissa (UHL) was associated with a patient who
previously had received colistin, while, the movement of the infected patients into the hospital probably
resulted to its spread.
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Background
Acinetobacter baumannii isolates are recognized as
major nosocomial pathogens; their ability to survive in
dry conditions and their resistance to disinfectants allow
these microorganisms to survive in the hospital environ-
ment [1, 2]. Carbapenems, which have been used to treat
infections caused by A. baumannii, are gradually being
inactivated by the emergence of resistant strains [3].
Various mechanisms involved in carbapenem-resistance of
A. baumannii include production of carbapenemases,
modification of antibiotic targets, overexpression of efflux
pumps and loss of porins [4]. Carbapenem-resistant strains
that are also simultaneously resistant to various, non-beta-
lactams antimicrobial agents pose important therapeutic
problem, due to the limited number of efficacious drugs
[5]. Colistin and tigecycline are often the only treatment
options for multiresistant A. baumannii infections but
resistance to both agents has recently been described, with
colistin resistance scattered worldwide [6–13].
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Colistin is rapidly bactericidal for Gram-negative
bacteria, interacting with the lipid A components of
lipopolysaccharide (LPS), resulting in the disorganization
of the outer membrane of bacteria [14]. However, the
wide usage of colistin, against carbapenem-resistant
multiresistant A. baumannii led to the development of
resistance [15]. In A. baumannii, colistin-resistance is
mediated by complete loss of LPS production via muta-
tions within the genes (lpxA, lpxC and lpxD) of the lipid
A biosynthesis pathway or by modification of lipid A
components of LPS via mutations in the pmrA and
pmrB genes of the two-component regulatory system
and pmrC that codes a lipid A phosphoethanolamine
transferase [16–20].
In the University Hospital of Larissa (UHL), that is the
main tertiary hospital of Thessaly (Central Greece) serving
a region of 1,200,000 habitants, enhanced systemic surveil-
lance resulted to a decrease of carbapenem-resistant A.
baumannii between 2012 and 2014 (2.6 cases in 2012 vs
2.1 cases in 2013 and 1.9 cases in 2014 respectively, per
1,000 patient-days). However, despite this encouraging
record, increased rate of colistin-resistance among A.
baumannii was observed. Aim of this study was to
determine the molecular characteristics of the isolates
(mechanisms of resistance and molecular typing) and
to describe the epidemiological traits.
Methods
Clinical isolates, identification and susceptibility testing
From January 2012 to December 2014, a total of 1228
consecutive A. baumannii isolates (494 in 2012, 407 in
2013 and 327 in 2014) were recovered from clinical
samples taken as part of standard care of an equal
number of individual patients admitted to the University
Hospital of Larissa, Thessaly (Central Greece). Only the
first isolate from each patient was included in this study.
In addition, ten environmental isolates, recovered during
2014 from 300 environmental cultures (100 from sink,
50 from patient beds, 50 from cupboards and 100 from
handle of door) from various wards of UHL, were also
included. Cotton-tipped swabs were moistened with sterile
saline and surfaces vigorously scrubbed. Potential fomites
included ventilator control panel and sensor, bed rails,
supply cabinets, computer keyboards and mice, curtains,
air vents, door handles, supply carts and mattresses.
Identification and susceptibility testing
Identification and antimicrobial susceptibility testing of
bacterial isolates was performed by the VITEK-2 system
(bioMérieux, Marcy l’Étoile, France). Determination of
MICs to colistin and fosfomycin were assessed by the
Etest method (bioMérieux, Marcy l’Étoile, France), while,
the interpretation was in accordance with the CLSI break-
points [21]. For isolates with MICs to colistin > = 4 mg/L
confirmation was done by broth microdilution method
according to CLSI guidelines [22]. Escherichia coli ATCC
25922 and Pseudomonas aeruginosa ATCC 27853 were
used as control strains [23].
Molecular assays
All A. baumannii, clinical and environmental, that
were classified as colistin-resistant using CLSI criteria
(MICs > =4 mg/L), were further analyzed for molecu-
lar typing and the underlying mechanisms of resist-
ance to colistin and to β-lactams.
a. Molecular typing
Molecular typing was done using primers for amplifying
and sequencing ompA, csuE and blaOXA-51-like gene
fragments as described previously [24].
b. Mechanisms for colistin and carbapenem resistance
The strains were screened for the presence of mutations
in the lpxA, lpxC, lpxD and pmrCAB genes, which have
been associated with the emergence of colistin resistance.
After DNA extraction by using the Quick-gDNA™
MiniPrep kit (ZYMO RESEARCH Corp., USA), the
genes were amplified by polymerase chain reaction
(PCR) as described previously [16, 19], and the PCR
amplicons were sequenced on both DNA strands using
an ABI3730 DNA sequencer (Applied Biosystems,
Warrington, United Kingdom). Nucleotide sequences of
lpxA, lpxC, lpxD and pmrCAB genes from colistin-
resistant isolates were compared with the respective
sequences obtained from three colistin-susceptible (MICs
to colistin 0.25 mg/ml,), belonging to the same clone as the
resistant strains, and with that of the reference strain
ATCC17978 (GenBank Accession Number CP000521).
The detection of blaIMP, blaVIM, blaGIM,, blaSIM, blaKPC,
blaNDM-1 and blaoxa-48, as well as bla oxa-23-like bla oxa-23-like,
blaoxa-24-like, bla oxa-51-like, bla oxa-58-like, was done by PCR as
described elsewhere [25].
Demographic data of patients
Demographic data (age, sex etc.) and clinical data of
patients diagnosed with colistin- resistant A. baumannii
infection were reviewed regarding their current and pre-
vious hospitalizations, previous antibiotic therapy, sites
of infection or colonization, comorbidities, outcome etc.
Ethics
Before obtaining the clinical information, all patients
sign the inform consent, while, approval was received
by the Ethics Committee of the UHL that is represented
by the Infection Control Committee (number of
permission 1334).
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Results
During the study period, 1116 carbapenem-resistant A.
baumannii (CR A. baumannii) were isolated. The rate
of carbapenem resistance was 93 % in 2012, 88 % in
2013 and 91 % in 2014, respectively, while, all
carbapenem-resistantisolates had MICs to imipenem
and meropenem >256 mg/L. On the other hand, the rate
of colistin resistance was 1 % in 2012, 2.9 % in 2013 and
21.1 % in 2014, while, an increase in MICmean value,
MIC50 and MIC90 was observed from year to year. In
more details, the MICmean value, MIC50 and MIC90 were
0.76, 0.48 and 0.49 mg/L in 2012, 1.44, 0.49 and 0.62 mg/L
in 2013 and 6.4, 0.65 and 3.3 mg/L in 2014, respectively.
Totally, eighty six A.baumannii clinical isolates were
identified as colistin- and carbapenem-resistant, with the
MICs of colistin ranging from 16 to 64 mg/L; they were
recovered from clinically significant samples (blood,
bronchial secretions etc.) from different patients of the
UHL and all were associated with infection according to
criteria [26–28]. Five and 12 of them were collected in
2012 and in 2013, respectively, while the remaining 69
A. baumannii were eventually collected during 2014. All
were pan-resistant expressing simultaneously resistance
to fluoroquinolones and aminoglycosides, whereas, 13
and 40 % of them were susceptible to tigecycline and
fosfomycin, respectively. No decrease in resistance levels
of other antimicrobial agents was observed. On the other
hand, the environmental A. baumannii were carbapenem-
resistant, but only one was resistant to colistin.
Molecular characterization of the isolates (86 clinical
and one environmental) revealed that all belonged to
3LST ST101, that corresponds to the international
clonal lineage II, and carried the blaOXA-23 gene being
responsible for high level resistance to carbapenems
(MIC >256 mg/L). To investigate the mechanisms of the
observed high rate of resistance to colistin, all colistin-
resistant isolates were screened for the presence of
mutations in the lpxACD and pmrCAB genes. Sequen-
cing of lpx genes revealed the presence of four amino
acid substitutions (LpxA: Y131H; LpxC:C120R +N287D;
LpxD:E117K) in all colistin-resistant and colistin-
susceptible isolates, compared to the sequences of the A.
baumannii ATCC 17978. On the other hand, sequencing
of the pmrCAB genes detected two different patterns of
amino acid substitutions, that were not detected in the
ATCC 17978 strain, (i) PmrB:A138T +A226V +A444V;
PmrC:F150L + I212V + R332K +A354S +K515T (pattern
A; GenBank accession number KR024312) among colistin-
susceptible ST101 A. baumannii and (ii) PmrA:G54E;
PmrB:A138T +A226V +A444V; PmrC:R109H + F150L +
I212V + R332K +A354S +K515T (pattern B; GenBank
accession number KR024313) among colistin resistant
ST101 A. baumannii. This finding apparently underlines
the involvement of PmrA: G54E and PmrC: R109H
substitutions in the development of colistin resistance in A.
baumannii isolates of ST101. None of the substitutions,
found in lpxACD and pmrCAB genes, have been
previously reported.
According to the demographic data, the index case was
a 62 year- old man, hospitalized in the Department of
Internal Medicine (DIM) for a cellulitis in the abdominal
area, and empirically treated with intravenous colistin and
daptomycin; the tenth day of treatment, on 7th January
2012, the patient presented fever and the blood culture
obtained recovered a colistin/carbapenem resistant A.
baumannii. Few days later, two other DIM patients were
found to be infected by this microorganism, while, on
September, a fourth DIM patient, admitted from a Long
Term Care Facility (LTCR) of Thessaly, was diagnosed
with pyelonephritis due to this strain. Unfortunately, the
patient deteriorated and was transferred to the Intensive
Care Unit (ICU) of UHL; 10 days later, an ICU patient,
who had never been treated with colistin, developed VAP
(ventilator associated pneumonia) due to colistin/carba-
penem resistant A. baumannii. After the first detection of
this pan-resistant microorganism, the Infection Control
Committee of UHL applied enhanced hygiene and envir-
onmental cleaning measures. From October 2012 to
March 2013, no colistin-resistant A. baumannii were
detected in our hospital. However, between April and June
2013, two small outbreaks took place in both the ICU and
the DIM, including five and seven patients respectively.
Nevertheless, despite the strict prevention measures,
during 2014 several colistin/carbapenem resistant A.
baumannii., have been isolated in various wards of
UHL. Fosfomycin and or tigecycline were mainly used
for the treatment of these patients. Clinical information
and the outcome of the patients are described in Table 1.
Discussion
Acinetobacter baumannii is a particularly challenging
pathogen because it is associated with a high degree of
resistance, and it is difficult to eliminate its environmental
reservoir in healthcare settings [29]. Carbapenems are
considered first-line agents for the treatment of A.
baumannii infections, and therefore the rise of infec-
tions due to carbapenem-resistant strains is of particu-
lar concern [30]. Additionally, carbapenem-resistant
A. baumannii isolates are often susceptible to only 1
or 2 agents, making them extensively drug-resistant
(XDR) pathogens by definition [30]. The incidence of
XDR A. baumannii infections is continually rising
[31–33]. For severe XDR A. baumannii infections,
polymyxins are frequently used, and are considered by
most to be the drugs of choice [34]. Today, colistin-
resistant/carbapenem-resistant pan-resistant A. baumannii,
spread and cause nosocomial outbreaks [35–37].
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In UHL such as in all Greek hospitals, the rate of
carbapenem-resistant Klebsiella pneumoniae, Pseudomonas
aeruginosa and Acinetobacter baumannii is very high,
resulting to a wide usage of colistin [38]. Between 2012 and
2014, despite the strict prevention measures in our hospital,
the rate of colistin-resistant/pan-resistant A. baumannii
dramatically increased. All these isolates belonged to 3LST
ST101, a clone that predominates for long time in UHL
[39]. We note that, since 2011, all colistin-susceptible
carbapenem-resistant A. baumannii belong to clone ST101
as those exhibiting resistance. We suppose that under the
selective pressure of colistin this clone became resistant
and then, it was spread from patient to patient. Recently,
Mavroidi et al., reported two 3LST ST 101 colistin-resistant
A. baumannii recovered from patients hospitalized in a
tertiary Greek hospital in Athens [40].
In our study, the prevalence of colistin-resistant A.
baumannii in the environmental cultures was low.
Numerous studies have documented the presence of
Acinetobacter spp in the hospital environment, but
rates of positive cultures may vary widely, depending
on the epidemiological setting and on the places of
collection [1, 41]. Our environmental A. baumannii
strains originated mainly from the patient beds and the
bedside cupboards indicating that these places present risk
for nosocomial outbreaks. The ability of this microorganism
to form biofilms blocks its eradication from the surfaces by
the cleaning and promotes its persistence in the hospital
setting [42].
Previous studies have shown that resistance to colistin is
associated with mutations in pmrB gene [18, 19, 35, 37].
Interestingly, in our strains, colistin resistance was corre-
lated with mutations in pmrA and pmrC. However, a
further study is necessary to prove the involvement of the
G54E (PmrA) and R109H (PmrC) amino acid substitutions
in the development of colistin resistance in A. baumannii,
and to characterize the impact of the latter substitutions in
the modification of lipid A components. Of note was that,
acquisition of colistin resistance did not alter resistance to
other antibiotics, which is in agreement with previous
studies demonstrating that, in contrast to Lpx alterations,
mutations in pmrCAB do not result in increased suscepti-
bility to other antimicrobials [16, 35].
The UHL is the main tertiary care unit of Central Greece
and admits patients coming from different parts of the area;
therefore, there is a great risk of spreading this pan-
resistant clone in the entire region, concerning that this
clone consist part of the microbiota of the hospital. The
first four months of 2015, the rate of colistin/carbapenem
resistant A. baumannii continued rising dramatically and
reached to 52 % (data not shown). In order to limit this
dissemination, all patients before their discharge are tested
if they are colonized with colistin-resistant A. baumannii.
In addition, unnecessary transfer of patients from the
surrounding hospitals to UHL stopped. Until now, only few
colistin-resistant strains have been isolated from the local
hospitals and LTCFs of Central Greece.
Conclusions
In the present study, from 2012 till 2014, a significant
increase of colistin-resistant/carbapenem-resistant A.
baumannii in a tertiary care hospital in central Greece
was observed. All isolates belonged to 3LST ST101 clone
and their resistance to carbapenems and to colistin
was associated with the production of OXA-23-like
carbapenem-hydrolyzing class D β-lactamase and with
mutations in pmrA and pmrC genes, respectively.
Epidemiological data of the patients indicated that the
first detection of colistin-resistant/carbapenem-resistant
ST101 clone in UHL was associated with a patient who
had previously received colistin, while, the movement of
the infected patients into the hospital probably resulted to
its spread.
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